Market Research Logo

Dementia - Pipeline Review, H1 2016

Dementia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Dementia - Pipeline Review, H1 2016’, provides an overview of the Dementia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dementia
The report reviews pipeline therapeutics for Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Dementia therapeutics and enlists all their major and minor projects
The report assesses Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Dementia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Dementia
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dementia Overview
Therapeutics Development
Pipeline Products for Dementia - Overview
Pipeline Products for Dementia - Comparative Analysis
Dementia - Therapeutics under Development by Companies
Dementia - Therapeutics under Investigation by Universities/Institutes
Dementia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Dementia - Products under Development by Companies
Dementia - Products under Investigation by Universities/Institutes
Dementia - Companies Involved in Therapeutics Development
Adamas Pharmaceuticals, Inc.
AgeneBio Inc.
Alector LLC
AlzProtect SAS
Amarantus Bioscience Holdings, Inc.
Axon Neuroscience SE
Axovant Sciences Ltd.
BioArctic Neuroscience AB
Biogen, Inc.
Biotie Therapies Corp.
Boehringer Ingelheim GmbH
Chase Pharmaceuticals Corporation
Daewoong Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
FORUM Pharmaceuticals Inc.
H. Lundbeck A/S
Heptares Therapeutics Limited
Hyundai Pharmaceutical Co., Ltd.
Ildong Pharmaceutical Co., Ltd.
Immungenetics AG
ImStar Therapeutics Inc.
Integrative Research Laboratories Sweden AB
Intellect Neurosciences, Inc.
Intra-Cellular Therapies, Inc.
MediPost Co., Ltd.
Neuraltus Pharmaceuticals, Inc.
Neurimmune Holding AG
Neurodyn Inc.
Oryzon Genomics S.A.
Ovid Therapeutics Inc.
P2D Bioscience
Pacific Northwest Biotechnology, LLC
Pivot Pharmaceuticals Inc
Sinil Pharmaceutical Co., Ltd
Stelic Institute & Co., Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sylentis S.A.U.
TauRx Therapeutics Ltd.
WhanIn Pharmaceutical Co., Ltd.
Dementia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile
AADvac-1 - Drug Profile
Antisense Oligonucleotides to Inhibit microRNA for Neurology - Drug Profile
Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile
AVCRI-104P3 - Drug Profile
AZP-2006 - Drug Profile
BAN-0805 - Drug Profile
BI-409306 - Drug Profile
CB-2233 - Drug Profile
CB-8411 - Drug Profile
choline alfoscerate SR - Drug Profile
CPC-201 - Drug Profile
CPC-252 - Drug Profile
D-217 - Drug Profile
dehydroevodiamine hydrochloride - Drug Profile
Drugs for Dementia - Drug Profile
Drugs to Agonize c-MET for Dementia - Drug Profile
Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile
DWJ-1365 - Drug Profile
E-2609 - Drug Profile
eltoprazine - Drug Profile
encenicline hydrochloride - Drug Profile
FRM-0334 - Drug Profile
GIBH-130 - Drug Profile
Gln-1062 - Drug Profile
GTC-6000 - Drug Profile
gugulipid - Drug Profile
HOB-075 - Drug Profile
HTL-18318 - Drug Profile
IRL-752 - Drug Profile
ITI-007 - Drug Profile
KR-12 - Drug Profile
levetiracetam - Drug Profile
LH-026 - Drug Profile
LUAF-20513 - Drug Profile
MM-201 - Drug Profile
Monoclonal Antibodies for Dementia and Alzheimer's Disease - Drug Profile
Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile
NAT - Drug Profile
nelotanserin - Drug Profile
Neurostem - Drug Profile
NI-205 - Drug Profile
NI-308 - Drug Profile
NNC-269100 - Drug Profile
NP-001 - Drug Profile
OG-635 - Drug Profile
ORY-2001 - Drug Profile
OV-201 - Drug Profile
P-003 - Drug Profile
PD-2015 - Drug Profile
PD-2016 - Drug Profile
PD-2024 - Drug Profile
PD-2244 - Drug Profile
PD-61W3 - Drug Profile
Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile
PST-900 - Drug Profile
RVT-101 - Drug Profile
salicylamine - Drug Profile
SIN-1502 - Drug Profile
Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile
Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile
Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile
Small Molecules for Frontotemporal Dementia - Drug Profile
Small Molecules for Ophthalmology and CNS Disorders - Drug Profile
Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile
Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia - Drug Profile
Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease - Drug Profile
SND-14 - Drug Profile
SYN-120 - Drug Profile
Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile
TAK-070 - Drug Profile
TauC-3 - Drug Profile
TPI-287 - Drug Profile
TRx-0237 - Drug Profile
TTT-3002 - Drug Profile
WIB-1001C - Drug Profile
zonisamide - Drug Profile
Dementia - Recent Pipeline Updates
Dementia - Dormant Projects
Dementia - Discontinued Products
Dementia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Dementia, H1 2016
Number of Products under Development for Dementia - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2016
Dementia - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016
Dementia - Pipeline by AgeneBio Inc., H1 2016
Dementia - Pipeline by Alector LLC, H1 2016
Dementia - Pipeline by AlzProtect SAS, H1 2016
Dementia - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016
Dementia - Pipeline by Axon Neuroscience SE, H1 2016
Dementia - Pipeline by Axovant Sciences Ltd., H1 2016
Dementia - Pipeline by BioArctic Neuroscience AB, H1 2016
Dementia - Pipeline by Biogen, Inc., H1 2016
Dementia - Pipeline by Biotie Therapies Corp., H1 2016
Dementia - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Dementia - Pipeline by Chase Pharmaceuticals Corporation, H1 2016
Dementia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
Dementia - Pipeline by Eisai Co., Ltd., H1 2016
Dementia - Pipeline by FORUM Pharmaceuticals Inc., H1 2016
Dementia - Pipeline by H. Lundbeck A/S, H1 2016
Dementia - Pipeline by Heptares Therapeutics Limited, H1 2016
Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016
Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2016
Dementia - Pipeline by Immungenetics AG, H1 2016
Dementia - Pipeline by ImStar Therapeutics Inc., H1 2016
Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2016
Dementia - Pipeline by Intellect Neurosciences, Inc., H1 2016
Dementia - Pipeline by Intra-Cellular Therapies, Inc., H1 2016
Dementia - Pipeline by MediPost Co., Ltd., H1 2016
Dementia - Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2016
Dementia - Pipeline by Neurimmune Holding AG, H1 2016
Dementia - Pipeline by Neurodyn Inc., H1 2016
Dementia - Pipeline by Oryzon Genomics S.A., H1 2016
Dementia - Pipeline by Ovid Therapeutics Inc., H1 2016
Dementia - Pipeline by P2D Bioscience, H1 2016
Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H1 2016
Dementia - Pipeline by Pivot Pharmaceuticals Inc, H1 2016
Dementia - Pipeline by Sinil Pharmaceutical Co., Ltd, H1 2016
Dementia - Pipeline by Stelic Institute & Co., Inc., H1 2016
Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
Dementia - Pipeline by Sylentis S.A.U., H1 2016
Dementia - Pipeline by TauRx Therapeutics Ltd., H1 2016
Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Dementia Therapeutics - Recent Pipeline Updates, H1 2016
Dementia - Dormant Projects, H1 2016
Dementia - Dormant Projects (Contd..1), H1 2016
Dementia - Dormant Projects (Contd..2), H1 2016
Dementia - Dormant Projects (Contd..3), H1 2016
Dementia - Dormant Projects (Contd..4), H1 2016
Dementia - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Dementia, H1 2016
Number of Products under Development for Dementia - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report